期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 79, 期 2, 页码 182-194出版社
WILEY
DOI: 10.1111/bcp.12403
关键词
adherence; antiretroviral; drug interactions; human immunodeficiency virus; pharmacogenomics; therapeutic drug monitoring
资金
- ViiV Healthcare
- Janssen
- Merck Pty Ltd
- Gilead
- AbbVie
- Bristol Myers Squibb
The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据